When was Relyvrio approved by the FDA?

The U.S. Food and Drug Administration (FDA) approved Relyvrio for the treatment of adults with amyotrophic lateral sclerosis in 2022. The decision came just a few months after the medication gained its first approval in Canada, where it is sold under the brand name Albrioza.